在肥胖患者中,新型口服抗瘤药物是否剂量不足?
Lishi Lin1, Ellen K O van der Meer1, Neeltje Steeghs2
1Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
肥胖会影响口腔癌药物水平. 较高的体重与较低的crizotinib,imatinib和trametinib药物水平相关,这表明在肥胖患者中可能需要剂量升级.
科学领域:
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
- 肥胖医学 肥胖医学
背景情况:
- 关于肥胖如何影响口服向性结药物暴露的数据有限.
- 了解这些影响对于优化治疗疗效和安全至关重要.
研究的目的:
- 调查体重和体重指数 (BMI) 对特定口服瘤学药物的最低水平的影响.
- 探索药物暴露与肥胖患者特征之间的关系.
主要方法:
- 对1265名患者进行了回顾性队列研究,这些患者接受了精选的口服抗瘤药物治疗.
- 与体重和BMI相关的平稳状态低谷水平的分析.
- 使用了斯皮尔曼的相关性和费舍尔的精确测试.
主要成果:
- 对于crizotinib,imatinib和trametinib (p < 0.001) 发现了体重和最低水平之间的负相关性.
- 较高的体重 (>100公斤) 与crizotinib不足的最低水平有关.
- 在BMI类别之间没有观察到不充分的低谷水平的显著差异.
结论:
- 体重增加与克里佐替尼布,伊马替尼布和特拉美替尼布的血谷值降低有关.
- 对于体重较高的患者来说,剂量升级可能是必要的,以达到这些口服抗瘤药物的足够治疗水平.
更多相关视频
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
相关概念视频
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Obesity
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
